Gossamer Bio is a San Diego-based biotech that is readying for an initial public offering – and with a diverse pipeline including potential treatments for a severe type of asthma, pulmonary arterial hypertension and inflammatory bowel disease, this IPO could be particularly appealing to investors. However, despite the promise associated with this biotech, there are also a number of potential problems that prospective investors should be aware of. For more, CLICK HERE.
Flow Kana is a California-based company that is part of what today’s article notes is “a relatively new form of cannabis business [that] has emerged: a middleman that does not grow pot itself, but rather distributes it” – and leaked documents show that it is telling prospective investors that it expects to achieve profitability in 2020 and revenue in excess of $2 billion by 2022. For more on this powerful pot distributor, CLICK HERE.